Cargando…

Effect of prior therapy on tumor mutational burden in NSCLC

BACKGROUND: Higher tumor mutation burden (TMB) in advanced non-small cell lung cancer (NSCLC) is associated with superior outcomes with checkpoint inhibitor therapy. Tissue samples subject to TMB analysis may be acquired after DNA-damaging therapies such as chemotherapy or radiation. The impact of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jonna, Sushma, Vanderwalde, Ari, Nieva, Jorge, Poorman, Kelsey Anne, Saul, Michelle, von Buttlar, Xinyu, Hu, John Y., Liu, Stephen V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044473/ https://www.ncbi.nlm.nih.gov/pubmed/33889505 http://dx.doi.org/10.21037/tlcr-20-1076

Ejemplares similares

Population bias in somatic measurement of microsatellite instability status
por: Saul, Michelle, et al.
Publicado: (2020)

Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients
por: Vanderwalde, Ari, et al.
Publicado: (2018)

Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases
por: In, Gino K., et al.
Publicado: (2020)

Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition
por: Kudura, Ken, et al.
Publicado: (2023)

Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers
por: Ruel, Louis-Jacques, et al.
Publicado: (2022)

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing
por: Nagasaka, Misako, et al.
Publicado: (2023)

Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center
por: Choudhury, Noura J., et al.
Publicado: (2019)

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
por: Tian, Yanhua, et al.
Publicado: (2020)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022)

Personalized Medicine in Oncology; a Special Issue of the Journal of Personalized Medicine
por: VanderWalde, Ari
Publicado: (2021)

Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
por: Nieva, Jorge, et al.
Publicado: (2022)

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
por: Ishii, Hidenobu, et al.
Publicado: (2020)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
por: Garassino, Marina C., et al.
Publicado: (2022)

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab
por: Nie, Wei, et al.
Publicado: (2020)

Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer
por: Hsu, Robert, et al.
Publicado: (2023)

Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling
por: Leong, Tracy L., et al.
Publicado: (2023)

EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
por: von Buttlar, Xinyu, et al.
Publicado: (2021)

Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China
por: Ma, Yuhui, et al.
Publicado: (2020)

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Ma, Yuhui, et al.
Publicado: (2021)

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
por: Li, Wenjie, et al.
Publicado: (2023)

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients
por: Gu, Weiguang, et al.
Publicado: (2023)

Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
por: Stein, Matthew K., et al.
Publicado: (2021)

Nuclear physics: an introduction
por: Von Buttlar, Haro
Publicado: (1968)

Die Einstein-Rosen-Brücke: unterwegs zu außerirdischer Intelligenz
por: Johannes von Buttlar
Publicado: (1982)

Comparison of Chemotherapy vs Chemotherapy Plus Total Hysterectomy for Women With Uterine Cancer With Distant Organ Metastasis
por: Wang, Yuefeng, et al.
Publicado: (2021)

Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)
por: Ma, Xiaoting, et al.
Publicado: (2021)

Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor Cells
por: Turetta, Matteo, et al.
Publicado: (2018)

Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
por: Barr, Martin P., et al.
Publicado: (2022)

Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting
por: VanderWalde, Ari, et al.
Publicado: (2020)

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
por: Judd, Julia, et al.
Publicado: (2021)

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies
por: Scheffler, Matthias, et al.
Publicado: (2014)

Rescue of Non-Informative Circulating Tumor DNA to Monitor the Mutational Landscape in NSCLC
por: Mayer, Stefanie, et al.
Publicado: (2020)

Neutrino power: der experimentelle Nachweis der Raumenergie revolutioniert unser Weltbild
por: Von Buttlar, Johannes, et al.
Publicado: (2000)

Racial disparities in patient survival and tumor mutation burden, and the association between tumor mutation burden and cancer incidence rate
por: Zhang, Wensheng, et al.
Publicado: (2017)

Tumor mutation burden: from comprehensive mutational screening to the clinic
por: Galuppini, Francesca, et al.
Publicado: (2019)

Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas
por: Yu, Guangyang, et al.
Publicado: (2021)

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
por: Peters, Solange, et al.
Publicado: (2022)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2021)

Tumor mutational burden in lung cancer: a systematic literature review
por: Willis, Connor, et al.
Publicado: (2019)

Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies
por: Müller, Katharina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_30nkvcarlqe9h8k6p61njti2le